Biotechnology and Healthcare: A New Dawn? With Bob Bradway, CEO of Amgen

Biotechnology and Healthcare: A New Dawn? Wit...

Money Maze PodcastMoney Maze Podcast

Up next

The Region that Defies Prediction. The Middle East’s Past Upheavals and the Storms Yet to Break. With Author Simon Sebag Montefiore

Today we welcome a reappearance of author Simon Sebag Montefiore. These few lines set the tone for an outstanding book and brilliant guest:“But even in easier times, the Middle East has the ability to surprise even the most informed observers and intelligence maestros. After all, ...  Show more

 . 1h 2min
Fraud, Fees and Fake Degrees! Where is the Allocation to Alternatives Headed? Albourne’s CEO, John Claisse, Explains their approach, Why Due Diligence Matters, and Where the Investment Flows are Secular, Not Cyclical.

John Claisse explores the evolution of alternative investing, from private markets and hedge funds to AI, digital assets, due diligence and opportunities across Asia.Albourne has expanded from its genesis in Sussex in 1994, to one of the most recognized global investment advisors ...  Show more

 . 59min 2sec

Recommended Episodes

Human Health: Society and the Future of Biotech
The Next Five

Biotechnology is the use of biology in the production of new products, services, and organisms with the aim of improving human health and society. In 2024, the global biotech market was worth $1.68 trillion. By application, the health segment was responsible for just over half of ...  Show more

 . 30min 35sec
China’s Biotech Revolution
Thoughts on the Market

Our China Healthcare Analyst Jack Lin discusses how China’s biotech surge is reshaping healthcare, investment and innovation worldwide.Read more insights from Morgan Stanley.----- Transcript ----- Jack Lin: Welcome to Thoughts on the Market. I'm Jack Lin, from Morgan Stanley's Ch ...  Show more

 . 3min 13sec
301: Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise
The Readout Loud

Oruka Therapeutics CEO Lawrence Klein joins us to discuss how his company raised its first round of financing before competing with major players in the inflammation space. We also discuss the latest news in the life sciences, including the end of the Amylyx ALS saga, another use ...  Show more

 . 31min 37sec
Novartis CEO: Medical Innovation, Tech Partnerships, and European Competitiveness
In Good Company with Nicolai Tangen

Can AI help us find cures for diseases we've never been able to treat? Nicolai Tangen speaks with Vasant 'Vas' Narasimhan, CEO of Novartis, about pioneering pharmaceutical innovation. They explore breakthrough cell and gene therapies, AI partnerships with leading tech companies, ...  Show more

 . 46min 34sec